Unlocking Hidden Pocket on a Billion‑dollar Drug Target

Why It Matters

Allosteric modulation of cereblon offers a route to enhance efficacy while reducing off‑target toxicity of existing cancer drugs, reshaping the targeted‑degradation market.

Key Takeaways

• Allosteric site on cereblon identified and structurally mapped.
• Allosteric ligand can enhance or inhibit substrate degradation.
• Modulation improves selectivity of thalidomide‑based therapies.
• Enables design of dual‑site molecular glues.
• Opens research into natural regulators of E3 ligases.

Pulse Analysis

Cereblon has become a cornerstone of the targeted protein degradation (TPD) platform, a strategy that repurposes the cell’s own ubiquitin‑proteasome system to eliminate disease‑causing proteins. Since the repurposing of thalidomide analogues for multiple myeloma, the market for cereblon‑recruiting agents has exploded, with several billion‑dollar pipelines in development. Yet, reliance on the orthosteric binding pocket has limited the ability to fine‑tune substrate selection, often leading to collateral protein loss and adverse events.

The Harvard‑GSK collaboration broke new ground by discovering a second, allosteric pocket on cereblon and demonstrating its functional relevance through high‑throughput cellular reporters and cryo‑EM structures. Occupancy of this pocket reshapes the protein’s conformation, creating an intermediate state that either amplifies or dampens the recruitment of neosubstrates. This mechanistic insight explains why the same orthosteric drug can exhibit divergent degradation profiles when paired with an allosteric ligand, offering a molecular dial for precision control.

For pharmaceutical developers, the allosteric site represents a strategic foothold to improve therapeutic windows. Add‑on modulators could be co‑administered with existing cereblon binders to sharpen target specificity and mitigate side‑effects, while next‑generation molecular glues might be engineered to engage both pockets simultaneously for enhanced potency. Beyond drug design, the discovery hints at endogenous regulators of E3 ligases, opening avenues for biomarker discovery and novel intervention points. As the TPD field matures, leveraging allosteric control may become a differentiator for companies seeking to capture market share in oncology and beyond.